MPS 14-05 Long-term cardiovascular prognosis of resistant hypertension defined by adherence criteria in Korean National Health Insurance Service – National Sample Cohort (NHIS-NSC)

2016 ◽  
Vol 34 (Supplement 1) ◽  
pp. e412
Author(s):  
Jinho Shin ◽  
Ki Seol Chang ◽  
Ki Chul Sung ◽  
Eun Mi Lee ◽  
Sang Hyun Ihm ◽  
...  
Keyword(s):  
Health Insurance ◽  
National Health Insurance ◽  
National Health ◽  
Resistant Hypertension ◽  
National Sample ◽  
Cardiovascular Prognosis ◽  
Korean National Health Insurance

scholarly journals The Associations of Tonsillectomy with Adenoidectomy with Pneumonia and Appendicitis Based on National Sample Cohort Data from the Korean National Health Insurance Service

2021 ◽  
Author(s):  
Junhui Jeong ◽  
Jung Kyu Choi ◽  
Hyun Seung Choi ◽  
Chang Eui Hong ◽  
Hyang Ae Shin ◽  
...  
Keyword(s):  
Risk Factors ◽  
Health Insurance ◽  
National Health Insurance ◽  
National Health ◽  
Significant Risk ◽  
National Sample ◽  
Population Based ◽  
Control Group ◽  
Number Of Patients ◽  
Korean National Health Insurance

Abstract Introduction The association between tonsillectomy with adenoidectomy (T&A) with appendicitis is controversial, and the association of T&A with pneumonia has not been investigated. Objective To investigate the associations of T&A with pneumonia and appendicitis using data from the Korean National Health Insurance Service National Sample Cohort. Methods We selected patients between the ages of 3 and 10 years who had undergone T&A in 2005 and were monitored since the performance of the T&A until 2013. The control group was established to have similar propensities for demographic characteristics compared to the T&A group. For eight years after the T&A, the number of patients with a diagnosis of pneumonia, patients who were admitted due to pneumonia, and those who underwent appendectomy were analyzed. The risk factors for pneumonia and appendectomy were analyzed. Results The number of pneumonia diagnoses was significantly higher in the T&A group than in the control group (p = 0.023), but there were no significant differences in the number of admissions due to pneumonia between the 2 groups (p = 0.155). Younger age and T&A were significant risk factors for the development of pneumonia. There were no significant differences in the number of appendectomies between the T&A and the control groups (p = 0.425), neither were there significant risk factors for appendectomy. Conclusion Tonsillectomy with adenoidectomy was associated with an increase in pneumonia diagnoses, but it was not associated with the number of appendectomies. The associations of T&A with pneumonia and appendicitis were analyzed in this population-based study.

Fenofibrate or omega-3 fatty acid use is associated with lower long term outcomes from propensity matched analysis of 141972 patients with diabetes in Korean national health insurance cohort

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
S.H Jo ◽  
H.S Kim ◽  
S.J Han ◽  
S.A Kim
Keyword(s):  
Health Insurance ◽  
Fatty Acid ◽  
National Health Insurance ◽  
National Health ◽  
Cardiac Death ◽  
Omega 3 ◽  
Omega 3 Fatty Acid ◽  
Patients With Diabetes ◽  
Korean National Health Insurance

Abstract Background We investigated the clinical effectiveness of fenofibrate or omega 3-fatty acid in patients with diabetes for long term. Methods Using Korean National Health Insurance data base, 141972 eligible patients with diabetes were selected. We divided the patients into 2 groups with propensity matching 1:2 ratio, fenofibrate/omega 3 fatty acid users (Fen-O, n=42353) or no users (n=14880). We followed up for 6-years for primary endpoint of death, myocardial infarction (MI), stroke and individual outcomes including cardiac death. Results Primary endpoint was significantly lower in Fen-O group as compared to no users, 2.35% vs. 1.58% (HR 0.673, CI: 0.633–0.715, P<0.001) in crude and 2.35% vs. 1.58% (HR 0.641, CI: 0.565–0.728) after adjusting age, sex, medical history analysis, body mass index, LDL-C and HDL-C). All cause death (0.76% vs. 1.24% [HR 0.664, CI: 0.625–0.706], p<0.0001), cardiac death (0.11% vs. 1.19% [HR 0.610, CI: 0.486–0.765, p=0.0001) and stroke (0.57% vs. 0.79%, [HR 0.723, CI: 0.594–0.881, P=0.0013) were significantly lower in Fen-O group. In the survival analysis, Fen-O group showed significantly lower primary outcome rate which is proportional with the days of intaking fenofibrate or omega 3 fatty acid (log rank <0.001), Conclusions Use of fenofibrate or omega 3 fatty-acid was associated with lower rate of composite of death, MI, stroke in diabetes patient for 6 year follow-up with large population. Funding Acknowledgement Type of funding source: None

Sign in / Sign up

Export Citation Format

Share Document